The Latest Breaking News from AXSM

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

Axsome reported strong fourth-quarter sales Tuesday, but AXSM stock tumbled on a setback for the company's Alzheimer's agitation treatment.

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….

The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA).  SVB Leerink says its view on Sunosi has not changed.

The Food and Drug Administration could be nearing a decision on Axsome Therapeutics' depression treatment, and AXSM stock rocketed Monday.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine.  The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Axsome Therapeutics will report an earnings per share (EPS) of $-1.00.